BioMarin The Courier / Apr 26, 2021
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
BioMarin News
The Courier
BioMarin Clark County Blog / Apr 25, 2021
The most advanced study released by Courant Market Research named Global Phenylketonuria (PKU) Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 comprises a comprehensive collection that covers thorough and considerable insights into past, present, and futuristic timeframe of the market.
BioMarin MarketBeat / Apr 24, 2021
Wall Street brokerages forecast that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post $0.32 earnings per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for BioMarin Pharmaceutical's earnings. The highest EPS estimate is $0.42 and the lowest i
MarketBeat
BioMarin Equities.com / Apr 24, 2021
Biomarin Pharmaceuticals (NASDAQ: BMRN) shares fell -1.22% to end trading Friday at $78.73 per share - a net change of $-0.97. Shares traded between $80.19 and $78.60 throughout the day. 733856 shares of Biomarin Pharmaceuticals exchanged hands. Visit Biomarin Pharmaceuticals's profile for more information.
BioMarin KSU | The Sentinel Newspaper / Apr 24, 2021
The latest well-composed research documentation titled Global Morquio Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026 offers a market synopsis covering key developments in the historical timelines based on which futuristic investment decisions are channelized. The report includes all the necessary data and provides complete guidance to readers and competitors.
KSU | The Sentinel Newspaper
BioMarin SoccerNurds / Apr 24, 2021
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, "Global Phenylketonuria Drug Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application ". The research report gives the potential headway openings that prevails in the global Phenylketonuria Drug market.
BioMarin MarketBeat / Apr 23, 2021
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Research analysts at Truist Securiti reduced their FY2021 EPS estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Tuesday, April 20th. Truist Securiti analyst R. Karnauskas now anticipates that the biotechnology co
BioMarin Equities.com / Apr 23, 2021
Biomarin Pharmaceuticals (NASDAQ: BMRN) shares gained 0.47% to end trading Thursday at $79.70 per share - a net change of $0.37. Shares traded between $80.18 and $78.29 throughout the day. 702034 shares of Biomarin Pharmaceuticals exchanged hands. Visit Biomarin Pharmaceuticals's profile for more information.
BioMarin KSU | The Sentinel Newspaper / Apr 23, 2021
COHERENT MARKET INSIGHTS has added a new report titled Global Cell and Gene Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Cell and Gene Therapy market.
BioMarin KSU | The Sentinel Newspaper / Apr 23, 2021
The Global Turner Syndrome Drug Market Report recently published by Infinity Business Insights is a professional and in-depth study on the current state of the industry. Different exploratory techniques such as qualitative and quantitative analysis have been used to give data accurately.
BioMarin Yahoo Finance / Apr 22, 2021
BioMarin Pharmaceutical (BMRN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
BioMarin MarketBeat / Apr 22, 2021
BioMarin Pharmaceutical (NASDAQ:BMRN) will release its earnings data after the market closes on Thursday, April 29th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. BioMarin Pharmaceutical has set its FY 2021 After-Hours guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.
BioMarin KSU | The Sentinel Newspaper / Apr 22, 2021
To offer an in-depth outlook of the Lysosomal Storage Diseases Therapeutics market we have released a brand new statistical study on the Global Lysosomal Storage Diseases Therapeutics Market Research 2021-2027 to our robust database.
BioMarin KSU | The Sentinel Newspaper / Apr 22, 2021
Phenylketonuria (PKU) Market is created in this intelligence report. This comprehensive research report is a well-thought-out compilation of detailed market development and growth factors optimizing the path of continued growth in terms of exact product data, strategies, and market share of the leading companies in this particular market.
BioMarin The Courier / Apr 22, 2021
Home / Uncategorized /Global Pancreatic Enzyme Replacement Therapy Market Key Players, Size, Trends, Opportunities and growth Analysis 2027||Biomarin Pharmaceutical Inc., AbbVie Inc, Alexion Pharmaceuticals Inc., Horizon Pharma Public Limited Company,The major players covered in the pancreatic enzyme replacement therapy market report are Global Pancreatic Enzyme Replacement Therapy Market describes complete industry Outlook with in-depth analysis.
BioMarin KSU | The Sentinel Newspaper / Apr 22, 2021
Gene Editing Market size valued at USD 3.8 billion in 2021 and is expected to witness +14% CAGR from 2021 to 2028. Increasing advancements in gene editing technologies are anticipated to boost the market demand. Genes control heredity and provide the basic biological code to determine the specific function of cell.
BioMarin The Courier / Apr 22, 2021
Home / Get Sample PDF of at: https://www.theinsightpartners.com/sample/TIPRE00004605/ Key companies Included in Neurological Disorder Drugs Market:- Neurocrine Biosciences, Inc.,, Pfizer Inc.,, Biogen Inc.,, Teva Pharmaceutical Industries Ltd.,, AcelRx Pharmaceuticals, Inc.,, Eli Lilly and Company,, Adamas Pharmaceuticals, Inc.,, BioMarin Pharmaceutical Inc, AstraZeneca plc,, Novartis International AG.
BioMarin InvestorsObserver / Apr 21, 2021
BioMarin Pharmaceutical Inc. ( BMRN) stock is up 0.97% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator. In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis.
BioMarin MarketBeat / Apr 21, 2021
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 2,709 shares of the company's stock in a transaction that occurred on Monday, April 19th. The stock was sold at an average price of $79.58, for a total value of $215,582.22. Following the sale, the executive vice president now owns 71,149 shares of the company's stock, valued at approximately $5,662,037.42.
BioMarin The Courier / Apr 21, 2021
